Book contents
- Context, Principles, and Practice of Transgynecology
- Context, Principles, and Practice of Transgynecology
- Copyright page
- Dedication
- Contents
- Foreword
- Preface
- Contributors
- Abbreviations
- Section A Contextual Transgynecology
- Section B Practicing Transgynecology
- Section C Gynecological Surgery for Transgender Males
- Section D Sexuality and Contraception
- Section E Fertility and Reproduction
- Section F Impact of Gender-affirming Hormonal Therapy on Genital Organs
- Chapter 31 Changes to the Uterus from Supraphysiological Androgens
- Chapter 32 The Ovaries under Supraphysiological Androgen Exposure
- Chapter 33 The Vaginal and Neovaginal Microbiome under Androgen or Estrogen Exposure Respectively
- Section G Screening and Prophylaxis
- Transgynecology Index
- References
Chapter 31 - Changes to the Uterus from Supraphysiological Androgens
from Section F - Impact of Gender-affirming Hormonal Therapy on Genital Organs
Published online by Cambridge University Press: 22 December 2022
Book contents
- Context, Principles, and Practice of Transgynecology
- Context, Principles, and Practice of Transgynecology
- Copyright page
- Dedication
- Contents
- Foreword
- Preface
- Contributors
- Abbreviations
- Section A Contextual Transgynecology
- Section B Practicing Transgynecology
- Section C Gynecological Surgery for Transgender Males
- Section D Sexuality and Contraception
- Section E Fertility and Reproduction
- Section F Impact of Gender-affirming Hormonal Therapy on Genital Organs
- Chapter 31 Changes to the Uterus from Supraphysiological Androgens
- Chapter 32 The Ovaries under Supraphysiological Androgen Exposure
- Chapter 33 The Vaginal and Neovaginal Microbiome under Androgen or Estrogen Exposure Respectively
- Section G Screening and Prophylaxis
- Transgynecology Index
- References
Summary
The uterus is known to undergo changes following exposure to supraphysiological doses of androgens, which are the doses typically used by trans masculine persons on gender-affirming hormone therapy. Clinically, most experience rapid onset amenorrhea but occasionally bleeding lasts up to 3–6 months. Uterine specimens derived from hysterectomy samples at the time of gender-affirming hysterectomy while on supraphysiological testosterone are found to be normal to small in size with thin endometrial linings that are predominately in the proliferative phase; the second most common endometrial histology is atrophy. There is also variation in the androgen receptor expressivity of the endometrium and myometrium following supraphysiological testosterone exposure. Pathology including fibroids, polyps, and adenomyosis continue to be seen, as well as endometrial hyperplasia and malignancy, though none are at increased frequency compared to cisgender females.
- Type
- Chapter
- Information
- Context, Principles and Practice of TransGynecologyManaging Transgender Patients in ObGyn Practice, pp. 233 - 235Publisher: Cambridge University PressPrint publication year: 2022
References
Fritz, MA, Speroff, L. Clinical Gynecologic Endocrinology and Infertility. Philadelphia, PA: Lippincott Williams & Wilkins, 2012.Google Scholar
American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology. ACOG practice bulletin no. 194: polycystic ovary syndrome. Obstet Gynecol 2018;131(6):e157–e171. https://doi.org/10.1097/AOG.0000000000002656Google Scholar
Hembree, WC, Cohen-Kettenis, PT, Gooren, L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2017;102(11):3869–3903. https://doi.org/10.1210/jc.2017-01658Google Scholar
Simitsidellis, I, Saunders, PTK, Gibson, DA. Androgens and endometrium: new insights and new targets. Mol Cell Endocrinol 2018;465:48–60. https://doi.org/10.1016/j.mce.2017.09.022Google Scholar
Gibson, DA, Simitsidellis, I, Collins, F, Saunders, PTK. Androgens, oestrogens and endometrium: a fine balance between perfection and pathology. J Endocrinol 2020;246(3):R75–R93. https://doi.org/10.1530/JOE-20-0106CrossRefGoogle ScholarPubMed
Loverro, G, Resta, L, Dellino, M, et al. Uterine and ovarian changes during testosterone administration in young female-to-male transsexuals. Taiwan J Obstet Gynecol 2016;55(5):686–691.Google Scholar
Grimstad, FW, Fowler, KG, New, EP, et al. Uterine pathology in transmasculine persons on testosterone: a retrospective multicenter case series. Am J Obstet Gynecol 2019;220(3):257.e1–257.e7.Google Scholar
Rose, GL, Dowsett, M, Mudge, JE, White, JO, Jeffcoate, SL. The inhibitory effects of danazol, danazol metabolites, gestrinone, and testosterone on the growth of human endometrial cells in vitro. Fertil Steril 1988;49(2):224–228. https://doi.org/10.1016/s0015-0282(16)59706-4Google Scholar
Zang, H, Sahlin, L, Masironi, B, Eriksson, E, Lindén Hirschberg, A. Effects of testosterone treatment on endometrial proliferation in postmenopausal women. J Clin Endocrinol Metab 2007;92(6):2169–2175. https://doi.org/10.1210/jc.2006-2171Google Scholar
Khalifa, MA, Toyama, A, Klein, ME, Santiago, V. Histologic features of hysterectomy specimens from female-male transgender individuals. Int J Gynecol Pathol 2019 (online). https://doi.org/10.1097/PGP.0000000000000548Google Scholar
Taub, RL, Ellis, SA, Neal-Perry, G, et al. The effect of testosterone on ovulatory function in transmasculine individuals. Am J Obstet Gynecol 2020;223(2):229.e1–229.e8. https://doi.org/10.1016/j.ajog.2020.01.059Google Scholar
Deutsch, MB, Bhakri, V, Kubicek, K. Effects of cross-sex hormone treatment on transgender women and men. Obstet Gynecol 2015;125(3):605–610. https://doi.org/10.1097/AOG.0000000000000692Google Scholar
Shim, JY, Laufer, MR, Grimstad, FW. Dysmenorrhea and endometriosis in transgender adolescents. J Pediatr Adolesc Gynecol 2020;33(5):524–528. https://doi.org/10.1016/j.jpag.2020.06.001Google Scholar
Grimstad, FW, Boskey, E, Grey, M. New-onset abdominopelvic pain after initiation of testosterone therapy among trans-masculine persons: a community-based exploratory survey. LGBT Health 2020;7(5):248–253. https://doi.org/10.1089/lgbt.2019.0258Google Scholar
James, SE, Herman, JL, Keisling, M, Mottet, L, Anafi, M. The Report of the 2015 US Transgender Survey. National Center for Transgender Equality, 2016.Google Scholar
Kanj, RV, Conard, LAE, Corathers, SD, Trotman, GE. Hormonal contraceptive choices in a clinic-based series of transgender adolescents and young adults. Int J Transgend 2019;20(4):413–420. https://doi.org/10.1080/15532739.2019.1631929Google Scholar
Group TECW. Ovarian and endometrial function during hormonal contraception. Hum Reprod 2001;16(7):1527–1535. https://doi.org/10.1093/humrep/16.7.1527Google Scholar
Catherino, WH, Eltoukhi, HM, Al-Hendy, A. Racial and ethnic differences in the pathogenesis and clinical manifestations of uterine leiomyoma. Semin Reprod Med 2013;31(5):370–379. https://doi.org/10.1055/s-0033-1348896Google Scholar